Cardiol Therapeutics Inc


Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx™, is a pharmaceutically produced extra strength oral cannabidiol formulation that is currently entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in 422 COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

Related content

Latest Analysis |

As Health Problems Mount Patients Welcome New Treatments

Healthcare is changing, as more and more diseases pose a growing concern for society and the companies trying to cure them.

Latest Analysis |

Tackling Recurring Health Conditions Offers Hope to Patients

Find out more about how Merck (NYSE: MRK), Bio-Techne Corporation (NASDAQ: TECH), Natera (NASDAQ: NTRA) and Cardiol Therapeutics (NASDAQ: CRDL)...

Press Releases |

Cardiol Therapeutics Appoints Two New Directors To Its Board

Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...

Press Releases |

Cardiol Therapeutics Announces FDA Investigational New Drug Application

Third IND authorization for CardiolRx™ in cardiovascular disease means this latest study will run in parallel with Company's multi-national Phase...

Latest Analysis |

Cardiol's Heart Failure Treatment Offers Hope to Diabetics

We're discussing diabetes and heart failure with reference to Eli Lilly & Co. (NYSE: LLY), Novo Nordisk (NYSE: NVO), Sanofi (NASDAQ: SNY) and...

Investing Ideas |

Biotech stock Cardiol Therapeutics makes progress with clinical trial

Cardiol Therapeutics advances CardiolRx trial with its first Covid-19 positive patient. The CBD formulation may hold the key to reducing CVD...

Press Releases |

Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-risk Patients Hospitalized with COVID-19

Cardiol Therapeutics announce that the first patient has been randomized in LANCER, a cannabidiol formulation being developed for chronic...

Press Releases |

Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx™

Press Releases |

Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options

Cardiol Therapeutics has submitted an application to uplist the Company’s common shares on The Nasdaq Capital Market® (the “Nasdaq”) and that it...

Investing Ideas |

Pharma’s $7.2 Billion CBD Acquisition Could Trigger New Biotech Boom

Investing Ideas |

How Cardiol Therapeutics Could Help Save the Most Vulnerable from Dying of COVID-19

Sign up for VTM Updates

Form submitted successfully!

VTM Exclusive Reports

Crypto Corner

Learn your NFTs from your BTCs